BioPark Regensburg GmbH

Booth number 4607-01

BioPark Regensburg GmbH is an enterprise of the City of Regensburg. Our key task is promoting biotechnology, medical engineering, diagnostics and analytics as well as healthcare.

About us

BioPark Regensburg GmbH is an enterprise of the City of Regensburg and part of the promotion of the economy. Our key task is promoting biotechnology, medical engineering, diagnostics and analytics as well as healthcare at the location and in the region.

To do this for one we operate a three laboratory building with an area of a total of 18,000 m2 on the grounds of the University of Regensburg, in which there are currently 35 leaseholders with 718 employees.

For another we coordinate the active cluster management of the Regensburg Bioregion from here with at this time 63 companies and 4,504 employees in East Bavaria. At the beginning of 2017 the BioPark brought the new brand name “Healthcare Regensburg” to life to be able to do justice to the collective visibility of the health location.

Today 10,955 employees work in 5 hospitals in the city and the district. A current study by the cluster shows that in 2019, 831 businesses in the Regensburg area generated sales of € 2.7 billion.

BioPark Regensburg GmbH
Am BioPark 13
93053 Regensburg

Phone: +49 941 920460
Fax: +49 941 9204624

News & Innovations

lifespin supports the startup scene at Harvard University in the United States (09/2021)

(No. 250) The company lifespin GmbH from BioPark Regensburg is a founding member of the Wyss Diagnostics Accelerator Program in the Industrial Participant Program at the renowned Harvard University in Cambridge in the USA. The program supports the development of breakthrough diagnostic technologies to improve disease screening management.

The company, founded in 2017 in the BioPark, is one of the so-called "deep data companies", i.e. an interdisciplinary team of today 17 employees combining diagnostic and bioanalytical methods with software solutions, including the use of artificial intelligence (AI). With the help of the most modern analyzes based on nuclear magnetic resonance technology, a database of metabolic profiles of more than 130,000 patients has already been built up, which already enables the analysis of more than a billion metabolic interactions.

The biotech company is expecting the first officially approved test for multiple sclerosis as early as next year. More tests for other neurological and cancer-related diseases are to follow.

Further reading
Development of the Health Industry in Regensburg (06/2021)

(No. 248) With the project "Healthcare Regensburg - managed by BioPark", a new initiative of the City of Regensburg was kicked off with the support of the Bavarian Ministry of Economic Affairs in the field of health management. A current study by the cluster shows that in 2019, 831 businesses in the Regensburg area generated sales of € 2.7 billion, thus documenting the growing importance of this industry for the future of the cathedral city and the Upper Palatinate region.

With increasing life expectancy, the increase in the average age in the population and progress in medical engineering, health care is becoming more and more important. The industry’s turnover in Germany was € 86.5 billion with an average growth rate of 5.37% per year. The largest share of sales is generated in inpatient and outpatient care for the elderly (42%), followed by hospitals (39%), natural medicine (11%), pharmacies (3%), resident medical (3%) and dental fields (2%). On behalf of the BioPark, the management and technology consultancy Detecon International GmbH carried out a study of the number of employees and sales in the City and District of Regensburg in the pharmaceutical and health sector. For this purpose, so-called WZ codes (classification and systematics of economic sectors) from the health sector were evaluated.

In 2020, a total of 21,600 employees with social security were working in the health sector in the Regensburg region. That is a good 33.8% more than in the 2011 census (see figure 1). At 55%, the largest proportion is employed in hospitals. 80% of the employees work in the urban area and 20% in the rural district.

Further reading
Current BioPark Annual Report 2021 (02/2022)

The current development of the life science companies in the BioRegio Regensburg shows a slightly increasing number of companies and a significant increase in the number of employees in East Bavaria in the second Corona year. The new business figures for 2021 presented by BioPark Regensburg GmbH count 63 companies and 4,504 employees for the cluster in Eastern Bavaria.

The companies in the cluster from the fields of biotechnology, pharmaceuticals and medical engineering, diagnostics, analytics and the healthcare industry were able to significantly expand their business in Eastern Bavaria in the second year of Corona and have increased their staff in many cases. This is shown by the current survey in the BioRegioRegensburg, which is conducted annually by BioPark Regensburg GmbH, a company of the City of Regensburg. The total number of companies in the cluster rose slightly compared to the previous year to 63 companies (+2). The total number of employees increased significantly from 4,093 to 4,504 (+10%). The BioPark is currently fully booked.

The technology and start-up center currently accommodates 35 leaseholders with almost 700 employees in its three buildings on a gross area of ​​18,000 m2. These include start-up companies, university and non-university institutions, companies from Germany and abroad, as well as service providers and our own daycare center.

Currently, 6 pharmaceutical companies with 1,530 employees, 30 medtech companies (medical engineering, diagnostics/analytics) with 2,124 employees and 27 biotech companies with 850 employees are active in the Regensburg Bioregion cluster.

Further reading

Click here if you notice an image that violates copyright or privacy rights.

Get in contact

We only use functionally necessary cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection